Skip to main content

Common molecular mechanisms underlying pathogenesis and treatment of human diseases

Thursday, October 11, 2012 — Concurrent Symposia Session IV

Noon – 2:00 p.m.

Conf. Room E1/E2


  • Minkyung (Min) Song, NCI
  • Joel Moss, NHLBI


Common pathogenic mechanisms of diverse diseases and similar clinical effects of their treatment with therapeutic interventions have been identified. It is timely to discuss this symposium topic as it addresses leveraging previous development of agents by exploring additional therapeutic indications to those agents that perturb common targets/pathways in multiple diseases. This topic is of broad interest to the NIH scientists as it facilitates discovery and development of therapeutic candidates that may benefit patients with diseases that share common pathogenic pathways. During this symposium, speakers will discuss: Role of the mammalian target of rapamycin pathway and targeting this pathway in diverse diseases; Clinical evaluation of an antibody against a common therapeutic target in several cancers; Exploring additional use of an anti-cancer drug in targeting a downstream pathway of hemolytic disorders; and Treatment approaches using molecular insights into pathogenesis of diseases and known mechanisms of action of several approved drugs.

Malaria infection depletes Erythrocyte Tetrahydrobiopterin, an essential cofactor for nitric oxide synthesis FARE Award Winner
Matthew Alkaitis, NIAID

Mammalian target of rapamycin (mTOR) as a target for therapeutic intervention in diverse diseases
Joel Moss, NHLBI

From cancer genetics to translational genomics: Genetic and functional association of Prostate Stem Cell Antigen (PSCA) gene with several cancers
Ludmila Prokunina-Olsson, NCI

Pleiotropic effects of intravascular hemolysis upon vascular homeostasis
Gregory Kato, NHLBI

Treatment for age-related macular degeneration by targeting diverse pathogenic pathways
Emily Chew, NEI

Willie Sutton's getaway car and the pathogenesis of Lewy body diseases
David Goldstein, NINDS

back to top